Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Lung Neoplasms 5Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Breast Neoplasms 3Tongue Neoplasms 2Rectal Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Lymphoma 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Carcinoma, Neuroendocrine 2Venous Thrombosis 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Sarcoma 1Salivary Gland Neoplasms 1Respiration Disorders 1Recurrence 1Pulmonary Embolism 1Pituitary Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Multiple Myeloma 1Mouth Neoplasms 1Lung Diseases 1Liver Diseases 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1

Interventions

regorafenib 1copper dotatate CU-64 1Irinotecan 1Fluorodeoxyglucose F18 1Etoposide 1Copper 1Clinical Trials, Phase II as Topic 1Cisplatin 164Cu-DOTATATE 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Gastro-enteropancreatic neuroendocrine tumor × Fluorodeoxyglucose F18 × Clear all
NCT05709171 2023-11-22

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Rigshospitalet, Denmark

Phase 2 Unknown
200 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡